Stephen Saad, Group Chief Executive, Aspen
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Adcock Ingram is a leading South African pharmaceutical manufacturer, listed on the Johannesburg Stock Exchange.
The Company manufactures, markets and distributes a wide range of healthcare products. The company is a leading supplier to both the private and public sectors of the market.
Adcock Ingram is a level 3 B-BBEE contributor.
Adcock Ingram Specialized Therapies is a specialized division that focuses on inspired therapeutic solutions, delivered through innovation that adds value to life, for life.
We provide leadership through solutions that support healthcare professionals to provide best-in-class specialist solutions for comprehensive patient care and the world’s leading and most trusted therapeutic brands.
The Prescription product range comprises medicines and technologies promoted to the healthcare professionals only. This portfolio includes a comprehensive range of generic medicines including antiretroviral medicines (ARVs). Partnerships with multinational pharmaceutical companies continue to augment the comprehensive portfolio of originator medicines.
Contact Details
Telephone: +27 11 635 0000
Physical address:
1 New Road,
Midrand 1685
South Africa
Postal address:
Private Bag X69,
Bryanston 2021
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Mr. Godard, you previously worked in Europe for Baxter Edwards Life Sciences, what made you decide to move to South Africa in a smaller company? It is a purely romantic…
Your professional career went back and forth between creating your own business and running a smaller and very dynamic structure and managing over a thousand of employees for multinational organizations.…
You were recently appointed at the head of Eli Lilly South African operations. What is the specific mission you have been given? Eli Lilly South Africa is in an interesting…
Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have you integrated these changes…
An emerging country with a dynamic market, South Africa is widely seen as the gateway to Africa. From major multinational pharmaceutical corporations to burgeoning local generic companies, a wide…
We interviewed Graham Somerville in 2004, the year when IHD, formerly jointly owned by 11 major pharmaceutical companies, was acquired by UTi. We are interviewing you today at the head…
Dr Pillay, South Africa recently became a member of BRICS. With this distinction, we need to improve our healthcare outcomes relative to other BRICS countries. All countries have challenges with…
The South African affiliate was established in June 2003. Could you come back on the main milestones in the company’s development from 2003 onwards? Yamanouchi as an entity was an…
Since we that came to South Africa in 2005 and interviewed you, what have been the main changes both in the market place, and within Sanofi as an organization? The…
In 2005, when Focus Reports interviewed you, you were more towards the start up phase of Pharma Dynamics; and you have significantly grown in the market since then. What new…
Mrs. Reid, how would you define and describe the generic part of the South African pharmaceutical market? Linda Reid: South Africa is very much a branded generics market, and not…
See our Cookie Privacy Policy Here
